Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | FES | P07332 | 1/20 | 0.33 |
| ▸ | FER | P16591 | 1/20 | 0.33 |
| ▸ | MARK3 | P27448 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.33 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7567012 | 1.00 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL654704 | 1.00 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL6066478 | 0.87 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL6066487 | 0.87 | LMNA (0.39) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL489379 | 0.83 | LMNA (0.58) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL6228572 | 0.82 | GAA (0.46) | LMNAGAABCAT1 | |
| SCHEMBL6228574 | 0.82 | GAA (0.46) | LMNAGAABCAT1 | |
| SCHEMBL6066470 | 0.81 | LMNA (0.41) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL8511462 | 0.81 | LMNA (0.41) | LMNAGAAOPRM1OPRK1ALOX5AP | |
| SCHEMBL6066480 | 0.81 | LMNA (0.41) | LMNAGAAOPRM1OPRK1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486189-B2 | TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-11-26 | — | — | US | disclosed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | disclosed |
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | KLEEMANN HEINZ-WERNER (DE) | 2002-04-18 | — | — | US | disclosed |
| US-6369236-B1 | DRUG FOR MEDICAL DIAGNOSIS ANTIARRHYTHMIC PROPRIETIES AND CONTAIN A CARDIOPROTECTIVE COMPOUND. THEY CAN PREVENTIVELY INHIBIT OR STRONGLY REDUCE PATHOPHYSIOLOGIC PROCESSES UPON OCCURRENCE OF ISCHEMIC INJURIES, ESPECIALLY ISCHEMIC CARDIAC | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-6335451-B1 | ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-01 | — | — | US | disclosed |
| US-5977155-A | CARDIOVASCULAR, KIDNEYS | HOECHST MARION ROUSSEL (FR) | 1999-11-02 | — | — | US | disclosed |
| US-5714508-A | INHIBITORS OF ANGIOTENSIN II | ROUSSEL UCLAF (FR) | 1998-02-03 | — | — | US | disclosed |
| US-5527919-A | Process for the preparation of 1-[(1,1'-biphenyl]-4-YL]-methyl-1H-imidazole-5-carboxylic acids | ROUSSEL UCLAF (FR) | 1996-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045761-A1 | Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them | BAX, BCL2, TNNI3 | LMNA 230/4885GAA 2799/4885OPRM1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.